Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
|
|
Reuters (12.21.01) - Thursday, December 27, 2001
Christopher Michaud
Earlier this year the US Food and Drug Administration (FDA), which regulates the $145 billion annual US prescription business, investigated and found some ads misleading. In April the agency sent an "advisory letter" to eight or nine drug makers, warning that their ads "didn't include important limitations associated with the products," said the agency's Nancy Ostrove. The offenders were warned against making claims or suggesting things the drugs cannot really do.
Often cited was an ad for Merck's protease inhibitor Crixivan that depicted several robust hikers who seemingly had just scaled a towering mountain peak. "If you're HIV positive, Crixivan may help you live a longer, healthier life," it said. Typical of activists' responses was that of Jeff Getty of Survive AIDS: "It's not about climbing mountains. It's about IV poles, wheelchairs and pain."
Since the FDA's letter, the ads have largely vanished - thinning out the gay magazines they once peppered, and with only the occasional torn poster still in subway stations. Newer ads contain caveats that the drugs have side effects and neither cure HIV nor prevent its transmission. But Joe Landry, publisher of the Advocate, Out and hiv plus, said it was "ludicrous" to blame the rise in unsafe sex on drug ads.
The drug companies note that the campaigns had outlived their useful lives and were being phased out even before the FDA's letter. Merck spokesperson Chris Loder said the company's direct-to-consumer ads are now "fully in compliance with the FDA." Landry said it was ironic that the drug companies pulled back "just when they needed to advertise - because of the rise in seroconversion."
011227
AD012238
Copyright © 2001 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.